RESUMEN
No disponible
Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Amputación Traumática/cirugía , Amputación Traumática/diagnóstico por imagen , Neoplasias del Recto/complicaciones , Pólipos/cirugía , Pólipos/diagnóstico por imagen , Inmunohistoquímica , Carcinoma/complicaciones , Carcinoma/cirugía , Dolor Abdominal/complicaciones , Hemorragia/complicacionesAsunto(s)
Adenocarcinoma/fisiopatología , Pólipos del Colon/fisiopatología , Neoplasias del Recto/fisiopatología , Adenocarcinoma/complicaciones , Adenocarcinoma/diagnóstico , Adenocarcinoma/cirugía , Pólipos del Colon/complicaciones , Colonoscopía , Diverticulosis del Colon/complicaciones , Femenino , Hemorragia Gastrointestinal/etiología , Humanos , Persona de Mediana Edad , Neoplasias del Recto/complicaciones , Neoplasias del Recto/diagnóstico , Neoplasias del Recto/cirugíaRESUMEN
OBJECTIVE: This study aims to assess the efficacy of hormone therapy in patients with severe gastrointestinal bleeding due to multiple angiodysplastic lesions. PATIENTS AND METHODS: Between May 2010 and July 2017, we included 12 consecutive patients with anaemia or recurrent bleeding due to angiodysplasia who had been started on hormone therapy. The therapy given was a combination of levonorgestrel (between 0.10 and 0.25 mg) and ethinylestradiol (between 0.02 and 0.05 mg). We determined the mean number of transfusions required in the 6 months before and after the start of the treatment, as well as the mean haemoglobin levels, number of admissions for anaemia due to gastrointestinal bleeding and length of hospital stay in these periods. RESULTS: The mean age of patients included was 77.83 years old and 75% were male. The follow-up period after treatment initiation was 6 months. Of the 12 patients included, only one stopped the treatment owing to it not being effective. Overall, 83.3% of the patients reported subjective improvement. Furthermore, we found significant differences comparing before and after starting treatment regarding the mean number of transfusions (7±4.8 vs. 3.4±4.6; P=0.005), the mean haemoglobin levels (9.5±1.2 vs. 10.8±2.6; P=0.034) and the mean number of admissions (1.6±1.6 vs. 0.2±0.4; P=0.024). On the contrary, differences between pretreatment and post-treatment length of hospital stay were not significant. CONCLUSION: Hormone therapy is a potentially useful therapeutic tool in patients with refractory bleeding and anaemia due to angiodysplasia.
